pemetrexed,carboplatin,paclitaxel,vinorelbine,nivolumab,cisplatin,docetaxel,gemcitabine,ipilimumab,pembrolizumab
merck,bms
[]
 good news . let me ask you about this information overall survival did not differ significantly between the groups in this analysis and curves.
Médico, professor universitário e doutor pela UFRN. pós-doutorado pela Duke University. Gerente de Ensino e Pesquisa do HUOL/UFRN/EBSERH